New York, NY (PRWEB) September 13, 2013
Treatment rates for the 10 most prevalent chronic conditions in Brazil generally ranged between 19 percent and 40 percent, according to new findings from Kantar Health’s National Health and Wellness Survey (NHWS). The research will be presented today at the ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 4th Latin America Conference in Buenos Aires.
Among the most prevalent conditions in Brazil, only hypertension had a treatment rate above 50 percent, with 68 percent of patients being treated. However, many chronic conditions, particularly psychiatric ones, had poor treatment rates despite these conditions being significantly debilitating. The most debilitating chronic conditions according to respondents to the NHWS were depression (treatment rate: 39 percent), anxiety (24 percent) and insomnia (19 percent).
“Despite the high prevalence of chronic conditions in Brazil, treatment rates are particularly poor,” said Dave Pomerantz, Senior Vice President, Kantar Health. “The exception was hypertension, which may be related to the free distribution of medicine for hypertension via the Farmacia Popular do Brasil. However, many conditions—especially psychiatric conditions—have low treatment rates despite being associated with worse patient outcomes, meaning that, from a public health perspective, it’s imperative to place more emphasis on the proper management of chronic diseases in Brazil.”
Visit Kantar Health’s website to download the full poster, “Societal Unmet Needs in Brazil: Examining Prevalence, Treatment Rates and Health Outcomes.”
About the National Health and Wellness Survey (NHWS)
The study’s results were drawn from the 2011 and 2012 Brazil NHWS, a nationally representative, self-administered survey conducted annually. Topics covered include the health status, attitudes, behaviors and outcomes among adults 18 or older.
Kantar Health conducts the NHWS in the U.S., Europe, Asia and Latin America. The survey is the largest self-reported dataset in the healthcare industry.
About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech, and medical device and diagnostic companies. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.
Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit http://www.kantarhealth.com.